HORMONE REPLACEMENT IN MENOPAUSAL WOMEN

更年期女性的激素替代

• 批准号: 3767798
• 负责人: S M HARMAN
• 金额: --
• 依托单位: NATIONAL INSTITUTE ON AGING
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3767798
• 关键词: aging; body composition; combination chemotherapy; drug administration routes; drug adverse effect; endocrine pharmacology; estrogens; female; growth hormone releasing hormone; hormone regulation /control mechanism; hormone therapy; human old age (65+); human subject; human therapy evaluation; insulinlike growth factor; oral administration; osteoporosis; pathologic bone resorption; postmenopause; progestins; secretion; somatotropin; transdermal drug delivery

In a study of body composition, sex steroids, GH and IGF-I in postmenopausal women whose body fat distribution and body fat mass independently range from lower (gynoid) to upper (android) distribution and from lower (lean) to higher (obese) percent at, we have found increased percent body fat and a more android body fat distribution with increasing age. There were independent inverse correlations of waist to hip ratio, but not of age or body mass index (BMI), with 12 hour pulsatile GH levels and GHRH-stimulated GH levels, suggesting an age-independent decrease in GH secretion attributable to android habitus. After oral estrogen treatment, there was increase in spontaneous GH secretion, but transdermal estrogens tended to decrease mean GH peak amplitude, with no change in 12 h mean GH secretion. Oral, but not transdermal estrogens significantly reduced basal and stimulated IGF-I. Another study examining estrogen-progestin co-therapy in older women has shown significant decreases in total cholesterol and LDL cholesterol with increases in HDL cholesterol, but no changes in triglycerides, BMI, or blood pressures. Non-significant decreases in urinary and serum calcium are consistent with a decrease in bone resorption. Results to date are consistent with potential beneficial effects of ERT on osteoporosis and coronary vascular disease in older women. New studies are being initiated to evaluate the transition from pre- to postmenopause and the effects of GHRH and estradiol on bone and muscle in osteoporotic women.

在一项关于身体成分、性类固醇、GH 和 IGF-I 的研究中 绝经后女性的体脂分布和体脂量 独立范围从下（gynoid）到上（android）分布 从较低（瘦）百分比到较高（肥胖）百分比，我们发现 身体脂肪百分比增加，身体脂肪分布更加机器人化 年龄增加。腰围与腰围之间存在独立的负相关关系 臀围比，但不包括年龄或体重指数 (BMI)，具有 12 小时脉动 GH 水平和 GHRH 刺激的 GH 水平，表明与年龄无关 由于机器人习性导致 GH 分泌减少。口服后 雌激素治疗后，自发性 GH 分泌增加，但 透皮雌激素倾向于降低平均 GH 峰值幅度，但没有 12 小时平均 GH 分泌量的变化。口服雌激素，但不能透皮雌激素 显着降低基础 IGF-I 和刺激 IGF-I。另一项研究检查 雌激素-孕激素联合治疗对老年女性的效果显着 总胆固醇和低密度脂蛋白胆固醇降低，高密度脂蛋白胆固醇增加 胆固醇，但甘油三酯、体重指数或血压没有变化。 尿钙和血清钙的非显着降低与 骨吸收减少。迄今为止的结果与 ERT 对骨质疏松症和冠状动脉血管的潜在有益作用 老年妇女的疾病。正在启动新的研究来评估 从绝经前到绝经后的转变以及 GHRH 和 雌二醇对骨质疏松女性骨骼和肌肉的影响。